WCN 2026 28 - 31 March 2026

Effect of once-weekly semaglutide 1.0 mg on kidney outcomes by baseline characteristics: Exploratory data from the FLOW trial

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Chronic Kidney Disease
Congress poster
GLP-1 RA
Semaglutide
PHASE 3 (RCT)